Robert J. Motzer - Concepedia

Author

Robert J. Motzer

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

ALLAN J. PANTUCK, Bukowski, Ronald M, Figlin, Robert A, Motzer, R.J., Motzer, Robert, Motzer, Robert J., R J Motzer, R MOTZER, R Motzer, R. J. Motzer

1.6K

Publications

122.7K

Citations

147

H-Index

160

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Institut Gustave Roussy Dana-Farber Cancer Institute Cleveland Clinic Cornell University

About

Robert J. Motzer is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	82	312	36K
2	Health Sciences	32	64	3.7K
3	Education	1	1	68
4	Engineering	1	1	27
5	Natural Sciences	1	1	22

Robert J. Motzer

618

Publications

110.2K

Citations

140

H-Index

Page 1

	Year	Citations
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma Robert J. Motzer, Bernard Escudier, Saby George, New England Journal of Medicine	2015	5.8K
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, New England Journal of Medicine	2007	5.7K
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma Robert J. Motzer, Nizar M. Tannir, Osvaldo Arén Frontera, New England Journal of Medicine	2018	4.5K
Tumor mutational load predicts survival after immunotherapy across multiple cancer types Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari, Nature Genetics Cancer ImmunosurveillanceTumor HeterogeneityMedicineImmunologyPathology	2019	4.2K
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma Gary R. Hudes, Michael A. Carducci, Piotr Tomczak, New England Journal of Medicine	2007	3.6K
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Robert J. Motzer, Bernard Escudier, Stéphane Oudard, The Lancet UrologySurgical OncologyGenitourinary CancerMedicineCancer Treatment	2008	3K
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen, New England Journal of Medicine	2019	2.5K
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, Journal of Clinical Oncology	2009	2.2K
Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma Robert J. Motzer, Thomas E. Hutson, David Cella, New England Journal of Medicine	2013	1.9K
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Brian I. Rini, Bernard Escudier, Piotr Tomczak, The Lancet Comparative EffectivenessUrologyOncologyAxitinib Versus SorafenibGenitourinary Cancer	2011	1.8K

Page 1